<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01952535</url>
  </required_header>
  <id_info>
    <org_study_id>HMM0101</org_study_id>
    <nct_id>NCT01952535</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Study of Administrating Single Ascending Dose of HMS5552 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Medicine Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hua Medicine Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to determine the safety profiles, tolerability,
      pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy
      adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind and placebo-controlled safety study with single oral
      doses of HMS5552 given to healthy volunteers.

      The primary objective is to characterize the safety profiles of HMS5552 following single
      ascending doses (SAD) in healthy adult subjects.

      The secondary objectives include:

        1. To assess the pharmacokinetic profiles of HMS5552 after single dosing

        2. To assess the preliminary pharmacodynamic profiles of HMS5552

      Each study subject will receive a single oral dose of HMS5552. During each dosing, eight
      subjects will be allocated to receive HMS5552 and two subjects will be allocated to receive
      placebo treatment.

      Several doses of HMS5552 will be tested. Dose titration or reduction is determined for each
      cohort based on the safety and pharmacokinetic data obtained from the lower dose cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of HMS5552 will be assessed by adverse event monitoring, physical examinations, 12 lead ECGs, vital sign, and safety laboratory measurements.</measure>
    <time_frame>up to 72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The single dose pharmacokinetics of HMS5552 will be described by estimating parameters of AUCinf, AUC0-t, Cmax, Tmax, Ae, T1/2.</measure>
    <time_frame>up to 72 hours post-dose</time_frame>
    <description>Plasma will be collected at predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 36, 48 and 72 hour post-dose. Urine will be collected at predose, 0 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, and 48 to 72 hour post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables will include maximum change (%) in fasting plasma glucose level, AUC0-4 of fasting plasma glucose , AUC of percent reduction in fasting plasma glucose from baseline versus time curve, time of minimum glucose level</measure>
    <time_frame>up to 6 hours post‚Äêdose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HMS5552 dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of HMS5552 tablets (5~50mg) taken orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMS5552</intervention_name>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
    <arm_group_label>HMS5552 dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>HMS5552 dose 1</arm_group_label>
    <arm_group_label>HMS5552 dose 2</arm_group_label>
    <arm_group_label>HMS5552 dose 3</arm_group_label>
    <arm_group_label>HMS5552 dose 4</arm_group_label>
    <arm_group_label>HMS5552 dose 5</arm_group_label>
    <arm_group_label>HMS5552 dose 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male volunteers, 18 to 45 years of age

          -  BMI: 18 to 24 kg/m2

          -  Fasting plasma glucose: 3.9 to 6.1 mmol/L

          -  Glucose level at 2 hours following oral glucose tolerance test &lt;7.8 mmol/L

          -  HbA1c: 4 to 6.5%

          -  Normal supine blood pressure and normal ECG recordings

        Exclusion Criteria:

          -  Female with child-bearing potential

          -  Evidence of clinically-significant renal, cardiac, bronchopulmonary, vascular,
             gastrointestinal, allergic, neurologic, metabolic (diabetes, thyroid disorders,
             adrenal disease), immunodeficiency disorders, cancer, hepatitis or cirrhosis.

          -  Intake of grapefruit or anything that may affect liver enzyme function within 1 month
             prior to the dosing day

          -  Clinically-relevant deviation from normal in the physical examination

          -  Subjects with a medical disorder, condition or history of such that would impair the
             subject's ability to participate or complete this study in the opinion of the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XueNing LI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hua Medicine Limited</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

